[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352101-105":59,"doc-detail-352101-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","rethinking-pdac-from-immunological-silence-to-therapeutic-opportunity-review","Rethinking PDAC - from immunological silence to therapeutic opportunity - Review","","Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies, with only 13% of patients surviving five years after diagnosis. Poor outcomes arise from late detection, treatment resistance, spatial and phenotypic heterogeneity, and a highly immunosuppressive tumor microenvironment. PDAC behaves as an immunologically “cold” tumor with minimal immune infiltration, defective antigen presentation, and stromal barriers, limiting the effectiveness of immune checkpoint blockade when used alone. The review summarizes emerging strategies such as neoantigen-targeted vaccines, stromal modulation, and combination therapies, emphasizing biomarkers and immune profiling to enable rational patient stratification and therapeutic design.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rethinking-pdac-from-immunological-silence-to-therapeutic-opportunity-review/352101/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rethinking-pdac-from-immunological-silence-to-therapeutic-opportunity-review/352101.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why does PDAC have such a poor prognosis despite available therapies?","Question",{"text":113,"@type":114},"PDAC often presents late and shows strong resistance to conventional treatments. Its highly immunosuppressive tumor microenvironment, including spatial and phenotypic heterogeneity, contributes to poor outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is PDAC described in terms of immune responsiveness?",{"text":118,"@type":114},"PDAC is characterized as an immunologically “cold” tumor with minimal immune cell infiltration, defective antigen-presentation machinery, and stromal barriers that support immune evasion.",{"name":120,"@type":111,"acceptedAnswer":121},"Which immunotherapy approaches does the review highlight for PDAC?",{"text":122,"@type":114},"The review highlights neoantigen-targeted vaccines, stromal modulation, and combination therapies such as immune checkpoint blockade with chemotherapy, cytokine blockade, or kinase inhibitors, guided by predictive biomarkers and immune profiling.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352101,1790701471,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Review  \nPUBLISHED 11 August 2026  \nDOI 10.3389/fimmu.2026.1909191  \nOPEN ACCESS  \nEDITED BY  \nJuan Francisco Santibanez, University of Belgrade, Serbia  \nREVIEWED BY  \nTatjana Srdic-Rajic,  \nInstitute of Oncology and Radiology of Serbia, Serbia  \nXianfeng Hui,  \nXinxiang Medical University, China Cody L. Wolf,  \nUniversity of Virginia, United States  \n*CORRESPONDENCE  \nUday Kishore  \n [uday.kishore@uaeu.ac.ae](uday.kishore@uaeu.ac.ae)[ ](uday.kishore@uaeu.ac.ae)Basel K. Al-Ramadi  \n [ramadi.b@uaeu.ac.ae](ramadi.b@uaeu.ac.ae)[ ](ramadi.b@uaeu.ac.ae)RECEIVED 14 June 2026 REVISED 17 July 2026 ACCEPTED 17 July 2026 PUBLISHED 11 August 2026  \nCITATION  \nKali SK, Ramesh RPG, Alam A, Fernandez-Cabezudo MJ, Al-Awadhi AM, Kishore U and  \nAl-Ramadi BK (2026) Rethinking PDAC: from immunological silence to therapeutic opportunity.  \nFront. Immunol. 17:1909191 .  \ndoi: 10.3389/fimmu.2026.1909191  \nCOPYRIGHT  \n© 2026 Kali, Ramesh, Alam, FernandezCabezudo, Al-Awadhi, Kishore and AlRamadi. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nRethinking PDAC: from immunological silence to therapeutic opportunity  \nSuresh K. Kali 1, Remya P. G. Ramesh 2, Aftab Alam 1, Maria J. Fernandez-Cabezudo 3,4, Aydah M. Al-Awadhi 5,6, Uday Kishore 2,4* and Basel K. Al-Ramadi 1,4,7*  \n1 Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, 2 Department of Veterinary Medicine, United Arab Emirates University, Al Ain, United Arab Emirates, 3 Department of Biochemistry and Molecular Biology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, 4Zayed Center for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, 5 Division of Hematology and Oncology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates, 6 Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, 7ASPIRE Precision Medicine Research Institute Abu Dhabi, United Arab Emirates University, Al Ain, United Arab Emirates  \nPancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest malignancies, with only 13% of patients surviving ﬁve years after diagnosis. This poor prognosis stems from late detection, treatment resistance, spatial and phenotypic heterogeneity, and a highly immunosuppressive tumor microenvironment. Unlike immunogenic cancers, PDAC is an immunologically ‘cold ’ tumor, marked by minimal immune cell inﬁltration, defective antigen-presentation machinery, and stromal barriers. While immune checkpoint blockade (ICB) has shown success against various cancers, it has proven largely ineffective when used alone in PDAC. However, emerging research has identiﬁed promising new approaches, including neoantigen-targeted vaccines, stromal modulation, and combination therapies such as ICB with chemotherapy, cytokine blockade, and kinase inhibitors. The development of personalized immunotherapy approaches is being reﬁned by predictive biomarkers that assess factors such as T cell inﬁltration levels, antigenpresenting capacity, and the spatial immune cell landscape. Here, we review the immune landscape of PDAC, current and emerging immunotherapeutic strategies, and highlight the critical role of biomarkers and immune proﬁling inappropriately categorizing patients. Collectively, these insights provide a foundation for designing rational combination therapies to transform PDAC into a cancer that is more immunologically responsive and a","cbCaibxqFgiT9iGN","https://ap.wps.com/l/cbCaibxqFgiT9iGN","pdf",4787908,16,"English","# Introduction\n## Immune landscape and immunosuppressive tumor microenvironment\n## Current and emerging immunotherapeutic strategies","[{\"question\":\"Why does PDAC have such a poor prognosis despite available therapies?\",\"answer\":\"PDAC often presents late and shows strong resistance to conventional treatments. Its highly immunosuppressive tumor microenvironment, including spatial and phenotypic heterogeneity, contributes to poor outcomes.\"},{\"question\":\"How is PDAC described in terms of immune responsiveness?\",\"answer\":\"PDAC is characterized as an immunologically “cold” tumor with minimal immune cell infiltration, defective antigen-presentation machinery, and stromal barriers that support immune evasion.\"},{\"question\":\"Which immunotherapy approaches does the review highlight for PDAC?\",\"answer\":\"The review highlights neoantigen-targeted vaccines, stromal modulation, and combination therapies such as immune checkpoint blockade with chemotherapy, cytokine blockade, or kinase inhibitors, guided by predictive biomarkers and immune profiling.\"}]","Rethinking PDAC - from immunological silence to therapeutic opportunity - Review | PDF",1790097700,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/565df2acf2a2ac5bb7e16b9f9884b2fb.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91c1ab101f013f2794cfb51e82447bfa.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/820cb5202f5395468e001478da19b09b.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4aab8fb2e2be4c65c41f18f0e9dea85a.webp",980,1385]